Zeeshan Fatima, Dyuti Purkait, Suriya Rehman, Suchitra Rai & Saif Hameed. 2023. Biological and Environmental Hazards, Risks, and Disasters. Biological and Environmental Hazards, Risks, and Disasters
197
220
.
Soo Tein Ngoi, Anis Najwa Muhamad, Cindy Shuan Ju Teh, Chun Wie Chong, Kartini Abdul Jabar, Lay Ching Chai, Kin Chong Leong, Loong Hua Tee & Sazaly AbuBakar. (2021) β-Lactam Resistance in Upper Respiratory Tract Pathogens Isolated from a Tertiary Hospital in Malaysia. Pathogens 10:12, pages 1602.
Crossref
Sanjai Saxena, Manmohan Chhibber & Inder Pal Singh. (2019) Fungal Bioactive Compounds in Pharmaceutical Research and Development. Current Bioactive Compounds 15:2, pages 211-231.
Crossref
David L. Hughes. (2017) Patent Review of Manufacturing Routes to Fifth-Generation Cephalosporin Drugs. Part 1, Ceftolozane. Organic Process Research & Development 21:3, pages 430-443.
Crossref
Richard R. Watkins & Robert A. Bonomo. 2017. Infectious Diseases. Infectious Diseases
1203
1216.e2
.
Karen Bush & Patricia A. Bradford. (2016) β-Lactams and β-Lactamase Inhibitors: An Overview. Cold Spring Harbor Perspectives in Medicine 6:8, pages a025247.
Crossref
Audrey Chan, Jason Cross, Yong He, Blaise Lippa & Dominic Ryan. 2013. Drug Discovery. Drug Discovery
389
438
.
Gary J. Noel, Jason S. Kendler, Barry J. Hartman, Mark Macielag & Karen Bush. 2010. Infectious Diseases. Infectious Diseases
1340
1354
.
A. Bryskier. (2006) Relation activité-structure des agents antibactériens. Antibiotiques 8:3, pages 136-146.
Crossref
A. Bryskier & M. Lebel. 2005. Antimicrobial Agents. Antimicrobial Agents
222
268
.
André Bryskier. 2005. Antimicrobial Agents. Antimicrobial Agents
1183
1238
.
A. Bryskier. 2005. Antimicrobial Agents. Antimicrobial Agents
13
38
.
Egid Strehl & Frieder Kees. (2000) Pharmacological Properties of Parenteral Cephalosporins. Drugs 59:Supplement 3, pages 9-18.
Crossref
A. Bryskier. (2000) Perfecting the ring and extending the antibacterial spectrum: ‘the multiple generations’. Clinical Microbiology and Infection 6, pages 13-21.
Crossref
M. Wolff. (1998) Comparison of Strategies Using Cefpirome and Ceftazidime for Empiric Treatment of Pneumonia in Intensive Care Patients. Antimicrobial Agents and Chemotherapy 42:1, pages 28-36.
Crossref
Meridith E. Erwin, David Varnam & Ronald N. Jones. (1997) In vitro antimicrobial activity of RU-59863, A C-7 catechol substituted cephalosporin. Diagnostic Microbiology and Infectious Disease 28:2, pages 93-100.
Crossref
Javier Garau, Walter Wilson, Martin Wood & Jean Carlet. (1997) Fourth-generation cephalosporins: a review of in vitro activity, pharmacokinetics, pharmacodynamics and clinical utility. Clinical Microbiology and Infection 3, pages S87-S101.
Crossref
Michel Glauser, Marc Boogaerts, Catherine Cordonnier, Jan Palmblad & Pietro Martino. (1997) Empiric therapy of bacterial infections in severe neutropenia. Clinical Microbiology and Infection 3, pages S77-S86.
Crossref
Ronald N Jones, Fernando Baquero, Gaetano Privitera, Matsuhisa Inoue & Bernd Wiedemann. (1997) Inducible ?-lactamase-mediated resistance to third-generation cephalosporins. Clinical Microbiology and Infection 3, pages S7-S20.
Crossref
Andr? Bryskier. (1997) New concepts in the field of cephalosporins: C-3' quaternary ammonium cephems (Group IV). Clinical Microbiology and Infection 3, pages S1-S6.
Crossref
Andr? Bryskier. (1995) C-3?Quaternary Ammonium Cephems, a New Wave of Cephalosporins. Clinical Microbiology and Infection 1:1, pages 1-3.
Crossref
T. Midtvedt. 1995.
237
244
.
G. Dannhardt. (2006) DPhG 8. Symposium der Fachgruppe Pharmazeutische Chemie Chemotherapeutika vom 7.–9. März 1994 in Mainz. Pharmazie in unserer Zeit 23:3, pages 175-181.
Crossref